학술논문

Direct stenting with 3000iu heparin
Document Type
Article
Source
Acute Cardiac Care; 2003, Vol. 5 Issue: 4 p206-210, 5p
Subject
Language
ISSN
17482941; 1748295X
Abstract
In order to reduce vascular complications, the authors assessed safety and feasability of a new percutaneous transluminal coronary angioplasty (PTCA) strategy consisting of direct stenting with 3000iu heparin and immediate sheath removal.  Predicting factors of vascular complications during PTCA include heparin dosages, sheath dwell time and use of anti-glycoprotein (GP) IIb/IIIa. A simplified PTCA with direct stenting technique may allow the use of very low doses of heparin without anti-GPIIb/IIIa in selected cases.  From April 1999 to April 2000 all patients who underwent PTCA in the authors' center were screened. Exclusion criteria comprised a contraindication for direct stenting, primary PTCA for acute myocardial infarction (MI) and a TIMI (thrombolysis in myocardial infarction) grade zero flow. All other patients were included. They received 3000iu heparin before direct stenting whatever their current anticoagulation and their weight. The sheath was immediately removed using manual compression.  Out of 716 consecutive PTCA patients, 171 (24%) were enrolled in the study (198 sites). Complete protocol was achieved in 150 patients (88%). Activated clotting time during the procedure was 179±32 seconds. No subacute thrombosis or creatine kinase elevation was observed before discharge. Only two uncomplicated groin hematomas and two false aneurysms (one surgical repair) were noted.  This study shows that direct stenting with 3000iu heparin is safe. Immediate sheath removal can be performed with a low rate of major vascular complications. (Int J Cardiovasc Intervent 2003; 5: 206–210)

Online Access